S. 641Senate111th Congress (2009-2011)In Committee

Dehydroepiandrosterone Abuse Reduction Act of 2009

Introduced March 19, 2009

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
SenateIntro Referral Latest Action

Read twice and referred to the Committee on the Judiciary.

March 19, 2009

View full timeline
SenateIntro Referral

Introduced in Senate

March 19, 2009

SenateIntro Referral

Sponsor introductory remarks on measure. (CR S3553-3554)

March 19, 2009

SenateIntro Referral

Read twice and referred to the Committee on the Judiciary.

March 19, 2009

Floor Debate

17 members

What members said about S. 641 on the floor

5 Republicans12 Democrats
Lamar Alexander
Sen. Lamar AlexanderR-TN · Mar 19, 2009

Mr. President, on a day in a week when there is a lot of news where people are hurting in a serious economy, I have some good news to report, and it will just take me a few minutes to do it. Our…

Russell D. Feingold
Sen. Russell D. FeingoldD-WI · Mar 19, 2009

Mr. President, today I am introducing the Federal Death Penalty Abolition Act of 2009. This bill would abolish the death penalty at the Federal level. It would put an immediate halt to Federal…

Chuck Grassley
Sen. Chuck GrassleyR-IA · Mar 19, 2009

Mr. President, I remain very concerned about the continuing prevalence of performance-enhancing drugs in sports. The ongoing reports of the vast use of performance-enhancing drugs in professional…

Olympia J. Snowe
Sen. Olympia J. SnoweR-ME · Mar 19, 2009

Mr. President, I rise today to join Senator Bingaman to introduce legislation to rectify a long standing problem for community health centers and the millions of Americans who depend on them for…

Patty Murray
Sen. Patty MurrayD-WA · Mar 19, 2009

Mr. President, there are a number of factors that caused the economic recession we are faced with today. All of us know that. We can blame executives on Wall Street, who made reckless choices and…

Show 8 more
Jeff Bingaman
Sen. Jeff BingamanD-NM · Mar 19, 2009

Mr. president, I rise today with Senators Snowe and Sanders to introduce the Medicare Access to Community Health Centers, MATCH, Act of 2009. This legislation addresses a long standing payment issue…

Patrick J. Leahy
Sen. Patrick J. LeahyD-VT · Mar 19, 2009

Mr. President, this week, the Nation celebrates the fifth annual Sunshine Week--a time when open Government advocates raise their voices to renew the call for open and transparent Government. Our…

Orrin G. Hatch
Sen. Orrin G. HatchR-UT · Mar 19, 2009

Mr. President, I rise today to introduce the National Pain Care Policy Act of 2009. I am pleased to have worked with my good friend, Senator Chris Dodd, on this legislation that will create a…

Max Baucus
Sen. Max BaucusD-MT · Mar 19, 2009

Mr. President, over the past week, we have heard a lot about AIG paying out $165 million in bonuses to employees of its financial products unit. This is the same company that took $170 billion in…

Barbara A. Mikulski
Sen. Barbara A. MikulskiD-MD · Mar 19, 2009

Mr. President, I rise today to join Senator Bunning to introduce the Equity and Access for Podiatric Physicians Under Medicaid Act. I am proud to introduce this legislation that will ensure Medicaid…

Herb Kohl
Sen. Herb KohlD-WI · Mar 19, 2009

Mr. President, I rise today to introduce the Nursing Home Transparency and Improvement Act of 2009. My colleague, Senator Grassley, and I have worked on this legislation together. He is on the floor…

Christopher J. Dodd
Sen. Christopher J. DoddD-CT · Mar 19, 2009

Mr. President, I rise today to join my colleague from Utah, Senator Orrin Hatch, in introducing the National Pain Care Policy Act of 2009. This important legislation would make significant strides in…

Benjamin L. Cardin
Sen. Benjamin L. CardinD-MD · Mar 19, 2009

Mr. President, I rise today to introduce the Star- Spangled Banner Commemorative Coin Act. I am pleased that my colleague, the senior Senator from Maryland, is a co-sponsor. This legislation will…

Show 4 more
Jim Bunning
Sen. Jim BunningR-KY · Mar 19, 2009

Mr. President, today I am reintroducing an important piece of legislation that I have worked on for several years with Senator Mikulski from Maryland. I am pleased that she is joining me in…

Kent Conrad
Sen. Kent ConradD-ND · Mar 19, 2009

Mr. President, today I am introducing the Midwifery Care Access and Reimbursement Equity, M-CARE, Act of 2009 with my colleague, Senator Collins. For too many years, certified nurse midwives, CNMs,…

Tim Johnson
Sen. Tim JohnsonD-SD · Mar 19, 2009

Mr. President, today I introduced legislation, along with Senators Stabenow and Tester, that establishes a first-of-its-kind program to dedicate funds to advance important state wildlife recovery and…

Jack Reed
Sen. Jack ReedD-RI · Mar 19, 2009

Mr. President, I ask unanimous consent that the text of the bill be printed in the Record.

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued March 19, 2009

II

111th CONGRESS

1st Session

S. 641

IN THE SENATE OF THE UNITED STATES

March 19, 2009

Mr. Grassley introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To amend the Controlled Substances Act to prevent the abuse of dehydroepiandrosterone, and for other purposes.

1.

Short title

This Act may be cited as the Dehydroepiandrosterone Abuse Reduction Act of 2009.

2.

Dehydroepiandrosterone

(a)

In general

Part D of title II of the Controlled Substances Act (21 U.S.C. 841 et seq.) is amended by adding at the end the following:

424.

Civil penalties for certain dehydroepiandrosterone sales

(a)

In general

(1)

Sale

(A)

In general

Except as provided in paragraph (2), it shall be unlawful for any person to knowingly sell, cause another to sell, or conspire to sell a product containing dehydroepiandrosterone to an individual under the age of 18 years, including any such sale using the Internet.

(B)

Failure to check identification

If a person fails to request identification from an individual under the age of 18 years and sells a product containing dehydroepiandrosterone to that individual, that person shall be deemed to have known that the individual was under the age of 18 years.

(C)

Affirmative defense

It shall be an affirmative defense to an alleged violation of subparagraph (A) that the person selling a product containing dehydroepiandrosterone examined the purchaser's identification and, based on that examination, that person reasonably concluded that the identification was valid and indicated that the purchaser was not less than 18 years of age.

(2)

Exception

This section shall not apply to any sale made pursuant to a validly issued prescription.

(b)

Fines

(1)

In general

The Attorney General may impose a civil penalty on a person for violating subsection (a)(1)(A), including a violation of that subsection committed by an employee or agent of such person.

(2)

Maximum amount

A civil penalty imposed under paragraph (1) shall be—

(A)

not more than $1,000 for the first violation of subsection (a)(1)(A) by a person;

(B)

not more than $2,000 for the second violation of subsection (a)(1)(A) by a person; and

(C)

not more than $5,000 for the third violation, or a subsequent violation, of subsection (a)(1)(A) by a person.

(3)

Number of violations

If a person makes sales of dehydroepiandrosterone at more than 1 location or 1 Internet site, for purposes of determining the number of violations by that person under this subsection each individual location or Internet site operated by that person shall be considered a separate person.

(c)

Definition of identification card

In this section, the term identification card means an identification card that—

(1)

includes a photograph and the date of birth of the individual;

(2)

is issued by a State or the Federal Government; and

(3)

is considered acceptable for purposes of sections 274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B)(1) of title 8, Code of Federal Regulations (as in effect on or after the date of the enactment of the Dehydroepiandrosterone Abuse Reduction Act of 2009).

.

(b)

Regulations

(1)

Internet sales

Not later than 180 days after the date of enactment of this Act, the Attorney General of the United States shall promulgate regulations for Internet sales of products containing dehydroepiandrosterone to ensure compliance with section 424 of the Controlled Substances Act, as added by this Act.

(2)

Civil penalties

(A)

In general

Not later than 180 days after the date of enactment of this Act, the Attorney General of the United States shall promulgate regulations to carry out section 424 of the Controlled Substances Act, as added by this Act.

(B)

Contents

The regulations promulgated under subparagraph (A) shall—

(i)

provide for a range of fines for a retailer, based on whether the retailer or an employee or agent of that retailer has committed prior violations of section 424(a) of the Controlled Substances Act, as added by this Act; and

(ii)

require consideration of whether a fine to be imposed on a retailer should be reduced or eliminated based on—

(I)

the establishment and administration of an effective employee training program by a retailer relating to this Act and the amendments made by this Act; or

(II)

other actions taken by a retailer to ensure compliance with this Act and the amendments made by this Act.

(3)

Definition of retailer

In this subsection, the term retailer means a grocery store, general merchandise store, drug store, convenience store, or other entity or person whose activities as a distributor relating to products containing dehydroepiandrosterone are limited almost exclusively to sales for personal use, both in number of sales and volume of sales, either directly to walk-in customers or in face-to-face transactions by direct sales.

(c)

Technical and conforming amendment

The table of contents for the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Public Law 91–513; 84 Stat. 1236) is amended by inserting after the item relating to section 423 the following:

.

(d)

Effect on State law

This section and the amendments made by this section shall supersede any provision of the law of any State relating to the sale of dehydroepiandrosterone.